Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: Jemperli
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors. Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
Contraindications
8 documented side effects by frequency
8 Reddit threads analysed for DOSTARLIMAB
Overall Sentiment
Positive
Comparison Threads
0
Avg Post Score
19 upvotes
Most discussed side effects in community
Just want to re-iterate. I'm not a prophet. Not a teacher. I don't speak in front of live audiences. I have zero out of body experiences. No dreams. It's just me here. I'm like you, studying it. Everything I say is how I interpret it. If you're reading this, then, it's up to you to balance,
Here is another long look at the past couple of years. Take it as you may. This is a discussion, not a declaration of truth. This is an interpretation of what we know via statement and a hypothetical assembly of those words into what may be behind them. Let's try to put it together the way it cou
I copied here for convenience, the PR of 11/22/22: # "CytoDyn to Host R&D Update on Wednesday, December 7, 2022 VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- **CytoDyn Inc. (OTCQB: CYDY)** ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist w
I know I put out a post yesterday, but for the sake of consistency, I did not want a Sunday to pass without a signature post. I'm not yet ready to break that trend. So here you go. But, I am pleased to see more and more posters. In [last week's post](https://www.reddit.com/r/Livimmune/comments/1g
I’m starting carboplatin/paclitaxel and dostarlimab for endometrial cancer on Feb 18th. It will be 6 infusions every three weeks with the immunotherapy continuing every 6 weeks for 3 years if all goes as planned. My oncologist stated that most of her patients continue to work through chemo. I’m a fi
Hi Guys, I am Jon 39 from Germany. I was diagnosed with Lynch syndrome with an advanced rectal tumor at the age of 21. Cancer has been with my family for generations; my grandfather died of colon cancer at the age of 36 and my mother died at the age of 57. Since my diagnosis in 2007 and neoadjuvant
The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s National Priority Voucher,” a ticket to speedier reviews of drug candidates aligned with U.S. priorities. The announcement came as the Trump administration unveiled agreements with E
# Pipeline Development Acrivon Therapeutics specializes in oncology through its Acrivon Predictive Precision Proteomics (AP3) platform, which identifies compound-specific protein signatures to predict patient response. While the company positions AP3 as a repeatable discovery engine, it currently re
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
5 available comparisons
Dosage Forms
Tablet
Route
Intravenous